Countering the 'counterattack' hypothesis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed.

1. The Fas-FasL system: from apoptosis regulator to therapeutic target in autoimmunity, cancer, and transplantation.Immunologic research · 2026
   Review
2. Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.Journal of cell science · 2019
   Review
3. CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases.Frontiers in immunology · 2017
   Review
4. Challenges and future perspectives of T cell immunotherapy in cancer.Immunology letters · 2015
   Review
5. MicroRNA 196B regulates FAS-mediated apoptosis in colorectal cancer cells.Oncotarget · 2015
   Article
6. Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver.Gastroenterology · 2009
   Article
7. Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.Cancer immunology, immunotherapy : CII · 2008
   Article
8. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.Cancer gene therapy · 2007
   Article
9. Tumor counterattack: fact or fiction?Cancer immunology, immunotherapy : CII · 2005
   Review
10. FADD adaptor in cancer.Medical immunology (London, England) · 2005
    Article
11. Immunotherapy of cancer for the elderly patient: does allogeneic bone marrow transplantation after nonmyeloablative conditioning provide a new option?Cancer immunology, immunotherapy : CII · 2004
    Review
12. Death receptors in chemotherapy and cancer.Oncogene · 2004
    Review
13. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.World journal of gastroenterology · 2003
    Article
14. Natural selection of tumor variants in the generation of "tumor escape" phenotypes.Nature immunology · 2002
    Review
15. Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.The American journal of pathology · 2002
    Article
16. Cancer vaccines: progress reveals new complexities.The Journal of clinical investigation · 2002
    Review
17. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.The Journal of experimental medicine · 2002
    Article
18. Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.Immunology · 2002
    Article
19. Close association between Fas ligand (FasL; CD95L)-positive tumor-associated macrophages and apoptotic cancer cells along invasive margin of colorectal carcinoma: a proposal on tumor-host interactions.Japanese journal of cancer research : Gann · 2002
    Article
20. Assumptions of the tumor 'escape' hypothesis.Seminars in cancer biology · 2002
    Review

Corrections and comments

• Comment on
  Immune privilege or inflammation? Insights into the Fas ligand enigma.2001

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as